| | | |
| (Commission File No.) | (IRS Employer Identification No.) |
| Title of each class | | Trading symbol | | Name of each exchange on which registered |
| | “ |
|
Exhibit No.
|
Description
|
|
Press Release dated November 9, 2026.
|
|
|
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
| Ionis Pharmaceuticals, Inc. | ||
| Dated: November 9, 2026 | By: |
/s/ Patrick R. O’Neil |
| Patrick R. O’Neil | ||
| Executive Vice President, Chief Legal Officer and General Counsel | ||
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
|
2026
|
2025
|
2026
|
2025
| |||||||||||||
|
(amounts in millions)
|
||||||||||||||||
|
Total revenue
|
$ | 243 | $ | 157 | $ | 757 | $ | 740 | ||||||||
|
Operating expenses
|
$ | 373 | $ | 317 | $ | 1,107 | $ | 907 | ||||||||
|
Operating expenses on a non-GAAP basis
|
$ | 330 | $ | 286 | $ | 975 | $ | 816 | ||||||||
|
Loss from operations
|
$ | (130 | ) | $ | (160 | ) | $ | (350 | ) | $ | (167 | ) | ||||
|
Loss from operations on a non-GAAP basis
|
$ | (87 | ) | $ | (129 | ) | $ | (218 | ) | $ | (76 | ) | ||||
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
|
2026
|
2025
|
2026
|
2025
| |||||||||||||
|
Revenue:
|
(amounts in millions)
|
|||||||||||||||
|
Commercial revenue:
|
||||||||||||||||
|
Product sales, net:
|
||||||||||||||||
|
TRYNGOLZA sales, net
|
$ | 9 | $ | 32 | $ | 41 | $ | 57 | ||||||||
|
DAWNZERA sales, net
|
37 | 1 | 79 | 1 | ||||||||||||
|
ZANVASTRO sales, net
|
2 | - | 2 | - | ||||||||||||
|
Total product sales, net
|
48 | 33 | 122 | 58 | ||||||||||||
|
Royalty revenue:
|
||||||||||||||||
|
SPINRAZA royalties
|
69 | 56 | 167 | 158 | ||||||||||||
|
WAINUA royalties
|
7 | 13 | 34 | 33 | ||||||||||||
|
Other royalties
|
5 | 7 | 14 | 19 | ||||||||||||
|
Total royalty revenue
|
81 | 76 | 215 | 210 | ||||||||||||
|
Other commercial revenue
|
7 | 7 | 26 | 26 | ||||||||||||
|
Total commercial revenue
|
136 | 116 | 363 | 294 | ||||||||||||
|
Research and development revenue:
|
||||||||||||||||
|
Collaborative agreement revenue
|
103 | 31 | 356 | 414 | ||||||||||||
|
WAINUA joint development revenue
|
4 | 10 | 38 | 32 | ||||||||||||
|
Total research and development revenue
|
107 | 41 | 394 | 446 | ||||||||||||
|
Total revenue
|
$ | 243 | $ | 157 | $ | 757 | $ | 740 | ||||||||
| Full Year 2026 Guidance | Previous Guidance | New Guidance |
|
Total Revenue
|
$875-900 million | Unchanged |
|
TRYNGOLZA product sales, net
|
$100-110 million | ~$50 million |
|
DAWNZERA product sales, net
|
$110-120 million | Unchanged |
|
Operating loss on a non-GAAP basis
|
$425-475 million | Unchanged |
|
Cash, cash equivalents and short-term investments
|
>$1.6 billion | Unchanged |
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | |||||||||||||
|
Revenue:
|
||||||||||||||||
|
Commercial revenue:
|
||||||||||||||||
|
Product sales, net
|
$ | 48 | $ | 33 | $ | 122 | $ | 58 | ||||||||
|
Royalty revenue
|
81 | 76 | 215 | 210 | ||||||||||||
|
Other commercial revenue
|
7 | 7 | 26 | 26 | ||||||||||||
|
Total commercial revenue
|
136 | 116 | 363 | 294 | ||||||||||||
|
Research and development revenue:
|
||||||||||||||||
|
Collaborative agreement revenue
|
103 | 31 | 356 | 414 | ||||||||||||
|
WAINUA joint development revenue
|
4 | 10 | 38 | 32 | ||||||||||||
|
Total research and development revenue
|
107 | 41 | 394 | 446 | ||||||||||||
|
Total revenue
|
243 | 157 | 757 | 740 | ||||||||||||
|
Expenses:
|
||||||||||||||||
|
Cost of sales
|
3 | 2 | 9 | 8 | ||||||||||||
|
Research, development and patent
|
216 | 218 | 643 | 636 | ||||||||||||
|
Selling, general and administrative
|
154 | 97 | 455 | 263 | ||||||||||||
|
Total operating expenses
|
373 | 317 | 1,107 | 907 | ||||||||||||
|
Loss from operations
|
(130 | ) | (160 | ) | (350 | ) | (167 | ) | ||||||||
|
Other income (expense):
|
||||||||||||||||
|
Interest expense related to the sale of future royalties
|
(4 | ) | (18 | ) | (39 | ) | (55 | ) | ||||||||
|
Other income, net
|
24 | 49 | 73 | 70 | ||||||||||||
|
Loss before income tax benefit (expense)
|
(110 | ) | (129 | ) | (316 | ) | (152 | ) | ||||||||
|
Income tax benefit (expense)
|
- | - | (1 | ) | - | |||||||||||
|
Net loss
|
$ | (110 | ) | $ | (129 | ) | $ | (317 | ) | $ | (152 | ) | ||||
|
Basic and diluted net loss per share
|
$ | (0.66 | ) | $ | (0.80 | ) | $ | (1.92 | ) | $ | (0.95 | ) | ||||
|
Shares used in computing basic and diluted net loss per share
|
166 | 160 | 166 | 159 | ||||||||||||
|
Three months ended
September 30, |
Nine months ended
September 30,
|
|||||||||||||||
| 2026 | 2025 |
2026
|
2025
| |||||||||||||
|
(unaudited)
|
||||||||||||||||
|
As reported cost of sales according to GAAP
|
$ | 3 | $ | 2 | $ | 9 | $ | 8 | ||||||||
|
Excluding compensation expense related to equity awards (1)
|
- | - | - | (1 | ) | |||||||||||
|
Non-GAAP cost of sales
|
$ | 3 | $ | 2 | $ | 9 | $ | 7 | ||||||||
|
As reported research, development and patent expenses according to GAAP
|
$ | 216 | $ | 218 | $ | 643 | $ | 636 | ||||||||
|
Excluding compensation expense related to equity awards
|
(24 | ) | (21 | ) | (74 | ) | (61 | ) | ||||||||
|
Non-GAAP research, development and patent expenses
|
$ | 192 | $ | 197 | $ | 569 | $ | 575 | ||||||||
|
As reported selling, general and administrative expenses according to GAAP
|
$ | 154 | $ | 97 | $ | 455 | $ | 263 | ||||||||
|
Excluding compensation expense related to equity awards
|
(19 | ) | (10 | ) | (58 | ) | (29 | ) | ||||||||
|
Non-GAAP selling, general and administrative expenses
|
$ | 135 | $ | 87 | $ | 397 | $ | 234 | ||||||||
|
As reported operating expenses according to GAAP
|
$ | 373 | $ | 317 | $ | 1,107 | $ | 907 | ||||||||
|
Excluding compensation expense related to equity awards
|
(43 | ) | (31 | ) | (132 | ) | (91 | ) | ||||||||
|
Non-GAAP operating expenses
|
$ | 330 | $ | 286 | $ | 975 | $ | 816 | ||||||||
|
As reported loss from operations according to GAAP
|
$ | (130 | ) | $ | (160 | ) | $ | (350 | ) | $ | (167 | ) | ||||
|
Excluding compensation expense related to equity awards
|
(43 | ) | (31 | ) | (132 | ) | (91 | ) | ||||||||
|
Non-GAAP loss from operations
|
$ | (87 | ) | $ | (129 | ) | $ | (218 | ) | $ | (76 | ) | ||||
|
As reported net loss according to GAAP
|
$ | (110 | ) | $ | (129 | ) | $ | (317 | ) | $ | (152 | ) | ||||
|
Excluding compensation expense related to equity awards and related tax effects
|
(43 | ) | (31 | ) | (132 | ) | (91 | ) | ||||||||
|
Non-GAAP net loss
|
$ | (67 | ) | $ | (98 | ) | $ | (185 | ) | $ | (61 | ) | ||||
| (1) | Amounts appear as zero due to rounding in millions. |
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (unaudited) | ||||||||
|
Assets:
|
||||||||
|
Cash, cash equivalents and short-term investments
|
$ | 1,884 | $ | 2,677 | ||||
|
Contracts receivable
|
88 | 66 | ||||||
|
Other current assets
|
389 | 247 | ||||||
|
Property, plant and equipment, net
|
162 | 123 | ||||||
|
Right-of-use assets
|
228 | 239 | ||||||
|
Other assets
|
162 | 172 | ||||||
|
Total assets
|
$ | 2,913 | $ | 3,524 | ||||
|
Liabilities and stockholders’ equity:
|
||||||||
|
Current portion of deferred contract revenue
|
$ | 70 | $ | 74 | ||||
|
0% convertible senior notes due April 2026, net – current
|
- | 432 | ||||||
|
Liability related to sale of future royalties, net – current
|
138 | 12 | ||||||
|
Other current liabilities
|
227 | 265 | ||||||
|
0% convertible senior notes due 2030, net
|
754 | 751 | ||||||
|
1.75% convertible senior notes due 2028, net
|
570 | 568 | ||||||
|
Liability related to sale of future royalties, net
|
428 | 551 | ||||||
|
Long-term lease liabilities
|
262 | 262 | ||||||
|
Long-term obligations, less current portion
|
21 | 28 | ||||||
|
Long-term deferred contract revenue
|
49 | 92 | ||||||
|
Total stockholders’ equity
|
394 | 489 | ||||||
|
Total liabilities and stockholders’ equity
|
$ | 2,913 | $ | 3,524 | ||||
|
New Product Launches
|
||||
|
Program
|
Indication
|
Location
|
2026
|
2027
|
|
DAWNZERA
|
HAE
|
EU
|
Achieved
|
|
|
TRYNGOLZA
|
sHTG
|
U.S.
|
Achieved
|
|
|
EU
|
•
|
|||
|
ZANVASTRO
|
Alexander disease
|
U.S.
|
Achieved
|
|
|
HIBSAGO
|
CHB
|
Japan
|
Achieved
|
|
|
U.S.
|
•
|
|||
|
EU
|
•
|
|||
|
China
|
•
|
|||
|
Sefaxersen
|
IgAN
|
U.S.
|
•
|
|
|
Ulefnersen
|
FUS-ALS
|
U.S.
|
•
|
|
| Regulatory Actions | ||||
|
Program
|
Indication
|
Regulatory Action
|
2026 | 2027 |
|
Donidalorsen
|
HAE
|
EU approval decision
|
Achieved
|
|
|
Olezarsen
|
sHTG
|
U.S. approval decision
|
Achieved
|
|
|
EU submission
|
Achieved
|
|||
|
EU approval decision
|
•
|
|||
|
Zilganersen
|
Alexander disease
|
U.S. submission
|
Achieved
|
|
|
U.S. approval decision
|
Achieved
|
|||
|
Nusinersen
(high dose) |
SMA
|
EU approval decision
|
Achieved
|
|
|
U.S. approval decision
|
Achieved
|
|||
|
Bepirovirsen
|
CHB
|
Regulatory submission(s)
|
Achieved
|
|
|
U.S. and Japan approval decisions
|
Achieved
|
|||
|
EU approval decision
|
• | |||
|
China approval decision
|
• | |||
|
Pelacarsen
|
Lp(a)- CVD
|
U.S. submission
|
Not Achieved | |
|
Sefaxersen
|
IgAN
|
U.S. submission
|
• | |
|
U.S. approval
|
• | |||
|
Ulefnersen
|
FUS-ALS
|
U.S. submission
|
• | |
|
U.S. approval
|
• | |||
|
Key Phase 3 Clinical Events
|
||||
|
Program
|
Indication
|
Event
|
2026
|
2027
|
|
Obudanersen
|
Angelman syndrome
|
REVEAL fully enrolled
|
Achieved
|
|
|
REVEAL data
|
•
|
|||
|
Bepirovirsen
|
CHB
|
B-Well data
|
Achieved
|
|
|
Pelacarsen
|
Lp(a)-CVD
|
Lp(a) HORIZON data
|
Not Achieved | |
|
Eplontersen
|
ATTR-CM
|
CARDIO-TTRansform data
|
Not Achieved
|
|
|
Sefaxersen
|
IgAN
|
IMAgINATION interim data
|
Achieved | |
|
IMAgINATION data
|
• | |||
|
Ulefnersen
|
FUS-ALS
|
FUSION data
|
Achieved | |
|
Salanersen
|
SMA
|
Phase 3 initiation
|
Achieved | |
|
Sapablursen
|
Polycythemia Vera
|
Phase 3 initiation
|
Achieved | |
|
Diranersen
|
Alzheimer’s disease
|
Phase 3 initiation
|
• | |